title: Sabal serrulata extract (Strogen forte) in the treatment of symptomatic benign prostatic hyperplasia.
abstract: The effectivity of Sabal serrulata extract in the treatment of symptomatic prostatic hyperplasia was scrutinized in 38 patients. In the course of the 12-month treatment followed up by examinations, the subjective complaints abated in almost 3/4 of the cases. Adverse effects were not encountered. According to uroflowmetry, the average peak flow rate increased from 10.36 ml/s to 14.44 ml/s (p < 0.0001), while the average middle stream increased from 6.02 ml/s to 7.45 ml/s (p < 0.001). Urinary retention decreased or disappeared in more than 9/10 of the cases. The average amount of the residue decreased by 47 ml (p < 0.001). The average volume of the prostate was reduced by 10.6% (p < 0.02). On the basis of the favourable results, Sabal serrulata extract is recommended in the treatment of prostatic hyperplasia producing symptoms of mild and moderate severity.
authors.affiliation: Department of Urological Surgery, Municipal Péterfy Sándor Street Hospital, Budapest, Hungary.
authors.forename: J
authors.initials: J
authors.lastname: Kondás
authors.forename: V
authors.initials: V
authors.lastname: Philipp
authors.forename: G
authors.initials: G
authors.lastname: Diószeghy
mesh_terms: D000368:Aged; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005227:Fatty Acids / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009929:Organ Size / Q000187:drug effects; D010840:Phytosterols / Q000627:therapeutic use*; D010936:Plant Extracts / Q000627:therapeutic use; D011467:Prostate / Q000473:pathology; D011470:Prostatic Hyperplasia / Q000175:diagnosis / Q000188:drug therapy*; D012720:Severity of Illness Index; D014563:Urodynamics / Q000187:drug effects*
chemical_list: D004791:Enzyme Inhibitors; D005227:Fatty Acids; C099102:IDS 89 Sabal serrulata extract; D010840:Phytosterols; D010936:Plant Extracts